Can-Fite BioPharma American Depositary Shares
CANF
6 hedge funds and large institutions have $1.77M invested in Can-Fite BioPharma American Depositary Shares in 2016 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 3 reducing their positions, and 3 closing their positions.
0% less ownership
Funds ownership: 0% → 0% (-0%)
25% less funds holding
Funds holding: 8 → 6 (-2)
34% less capital invested
Capital invested by funds: $2.66M → $1.77M (-$895K)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ARTA
A.R.T. Advisors
New York
|
+$27.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$705K |
| 2 |
Jane Street
New York
|
-$55.4K |
| 3 |
TAM
Taylor Asset Management
Toronto,
Ontario, Canada
|
-$34.6K |
| 4 |
Creative Planning
Overland Park,
Kansas
|
-$14K |
| 5 |
VKH
Virtu KCG Holdings
New York
|
-$6.93K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TAM
1
Taylor Asset Management
Toronto,
Ontario, Canada
| $1.54M | -$34.6K | -5 | -3% |
|
|
MC
2
Menta Capital
San Francisco,
California
| $106K | – | – | – |
|
|
VKH
3
Virtu KCG Holdings
New York
| $44K | -$6.93K | -1 | -17% |
|
|
ARTA
4
A.R.T. Advisors
New York
| $35K | +$27.7K | +4 | New |
|
|
5
Jane Street
New York
| $30K | -$55.4K | -8 | -67% |
|
6
Group One Trading
Chicago,
Illinois
| $6K | – | – | – |
|
|
MFS
7
MSI Financial Services
Springfield,
Massachusetts
| $3K | – | – | – |
|
|
TRCT
8
Tower Research Capital (TRC)
New York
| $1K | – | – | – |
|
|
9
Morgan Stanley
New York
| – | -$705K | -81 | Closed |
|
|
10
Creative Planning
Overland Park,
Kansas
| – | -$14K | -2 | Closed |
|
|
IA
11
IFP Advisors
Tampa,
Florida
| – | -$4K | -1 | Closed |
|
CANF Hedge Fund Activity: Q1 2016 in Review
6 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Can-Fite BioPharma American Depositary Shares (CANF) for Q1 2016, worth a combined $1.77M — down 34% from $2.66M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of CANF and 1 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 0 added.
The largest buyer was A.R.T. Advisors, opening a new position worth an estimated $27.7K. The largest seller was Morgan Stanley, exiting entirely with an estimated $705K sold.
- 6 institutional investors held Can-Fite BioPharma American Depositary Shares (CANF) as of Q1 2016, down from 8 in Q4 2015.
- Funds reported $1.77M of Can-Fite BioPharma American Depositary Shares stock for Q1 2016, down 34% quarter-over-quarter.
- 1 fund opened new Can-Fite BioPharma American Depositary Shares positions in Q1 2016 and 3 closed out, a net change of -2 holders.
- The largest Can-Fite BioPharma American Depositary Shares buyer in Q1 2016 was A.R.T. Advisors, an estimated $27.7K added.
- The largest Can-Fite BioPharma American Depositary Shares seller in Q1 2016 was Morgan Stanley, an estimated $705K sold.
Based on aggregated 13F filings for Q1 2016.